An interventional study of ARC-IM System implantation in Parkinson Disease, sponsored by Ecole Polytechnique Fédérale de Lausanne. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Ecole Polytechnique Fédérale de Lausanne · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.
Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 59th largest by planned enrollment of the 67 interventional ones that give a count, is one of 9 that started in 2024, is one of 49 with no phase, reaches primary completion later than 31 of the 33 other live ones, and was the 63rd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–75
Siegward -M. Elsas · Sites in Switzerland
Ages 50–79
University of Zurich · Sites in Switzerland
Ages 18+
University of Zurich · Sites in Switzerland
Alain Kaelin · Sites in Switzerland
Ages 50–80
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 4 · Phase 4 3
First in 2002; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 30 across the 67 interventional studies, 64 across the 18 observational. Of the 45 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 85 have an industry lead sponsor. The 10 most frequent:
Ecole Polytechnique Fédérale de Lausanne is the lead sponsor of 21 studies on the registry; 11 are open to participants now.
Ecole Polytechnique Fédérale de Lausanne has 3 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
12 of the studies in Parkinson Disease with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06831500Julien BallyFeasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. | 2026-11 |
| NCT07485218University of Applied Sciences and Arts of Southern SwitzerlandMultidimensional Assessment of Fatigability in Older Adults Living in Southern Switzerland and Elderly With Parkinson's Disease | 2026-12 |
| NCT06608875University of ZurichPrecision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops | 2026-12 |
| NCT05765110Insel Gruppe AG, University Hospital BernSPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease | 2026-12-31 |
| NCT07802509Klinik ValensDoes Hippotherapy Have an Effect on Mobility, Gait, Balance and Perceived Health-related Quality of Life in Persons With Parkinson's Disease? | 2027-01-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 85 studies in Parkinson Disease with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to assess the preliminary safety and efficacy of the ARC-IM spinal cord stimulation therapy in alleviating locomotor deficits in individuals with Parkinson's disease. The ARC-IM Therapy employs epidural electrical stimulation (EES) to modulate leg muscle recruitment, with the aim of improving mobility deficits. The ultimate goal is to enhance the quality of life of people with Parkinson's disease.
The progression of Parkinson's Disease (PD) is often marked by the development of severe locomotor deficits, including gait impairments, which significantly affect patients' independence and are not effectively addressed by current treatments. The STIMO-PARKINSON (NCT04956770) clinical trial has shown promising results with epidural electrical stimulation (EES) in significantly reducing these locomotor deficits in Parkinson's Disease patients.
Building on these findings, the SPARKL clinical study aims to further this research. The SPARKL study aims to enroll six individuals with advanced Parkinson's Disease to assess the safety and efficacy of the novel ARC-IM Therapy. This new therapy has been designed to overcome previous technological limitations and facilitate its home-use.
This study will take place at the Lausanne University Hospital (CHUV, Switzerland). The total duration of the study is 4 years per participant. The study intervention consists of several phases preceded by pre-screening. The first year involves an intensive participation, consisting of the following phases: enrolment and baseline, surgical implantation of the stimulation device, a main study phase that includes stimulation configuration sessions and both in-clinic and at-home rehabilitation, and finally the home-use phase. This will be succeeded by 3 years of safety follow-up, during which the participant can use the stimulation device in their daily life, subject to investigator approval.
Throughout the study, the investigators will conduct assessments at various stages of each participant's journey in the study. These assessments will be used to assess the preliminary safety and efficacy of the ARC-IM therapy at alleviating locomotor deficits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants enrolled in the study will receive the same intervention. The first year of the study consists of the following phases: enrolment, baseline assessments, surgical implantation of the ARC-IM stimulation device, configuration sessions for stimulation, in-clinic and at-home rehabilitation, and a home-use phase. It is followed by 3 years of safety follow-up. Assessments will be planned throughout the course of the study and at baseline, the end of the optimization phase, the end of the rehabilitation phase, and after 12 months post-surgery.
Device: ARC-IM System implantation
Implantation of a stimulation lead on the lumbar level of the spinal cord and implantation of a neurostimulator in the abdominal region.
Occurrence of serious adverse events and adverse events that are deemed related or possibly related to the study procedures or to the investigational system.
Assess the safety of the ARC-IM Therapy at alleviating locomotor deficits in people with Parkinson's Disease.
Time frame: From enrollment until end of safety follow-up phase (4 years)
10-meter walk test
To assess gait speed. Measurement tool: time (s)
Time frame: Baseline (before surgery), Short-Term assessments (~1 month post-surgery) and Follow-Up assessments (~4 & 11 months post-surgery)
6-minute walk test
To assess endurance. Measurement tool: distance (m)
Time frame: Baseline (before surgery), Short-Term assessments (~1 month post-surgery) and Follow-Up assessments (~4 & 11 months post-surgery)
Timed up and Go and its cognitive version
To assess freezing of gait prevalence. Measurement tool: time (s)
Time frame: Baseline (before surgery), Short-Term assessments (~1 month post-surgery) and Follow-Up assessments (~4 & 11 months post-surgery)
Freezing of gait circuit
To assess freezing of gait prevalence. Measurement tool: time (s)
Time frame: Baseline (before surgery), Short-Term assessments (~1 month post-surgery) and Follow-Up assessments (~4 & 11 months post-surgery)
Kinematic analysis
Gait circuit to assess gait kinematic. Measurement tool: changes in position and orientation of the body through sensors (mm)
Time frame: Baseline (before surgery), Short-Term assessments (~1 month post-surgery) and Follow-Up assessments (~4 & 11 months post-surgery)
Muscle analysis
Gait circuit to assess muscle activity. Measurement tool: muscle activity through sensors (mV)
Time frame: Baseline (before surgery), Short-Term assessments (~1 month post-surgery) and Follow-Up assessments (~4 & 11 months post-surgery)
Mini Balance Evaluation Systems Test (mini-BESTest)
4-item test to assess balance. Measurement tool: total score
Time frame: Baseline (before surgery), Short-Term assessments (~1 month post-surgery) and Follow-Up assessments (~4 & 11 months post-surgery)
Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
19 item-test to assess the course of Parkinson's Disease. Measurement tool: total score from 0 up to 132. Low score means a better outcome.
Time frame: Baseline (before surgery), Short-Term assessments (~1 month post-surgery) and Follow-Up assessments (~4 & 11 months post-surgery)
King's Parkinson's disease Pain Scale (KPPS)
7-item questionnaire to assess daily life performance. Measurement tool: total score 0 up to 168. Low score means a better outcome.
Time frame: Baseline (before surgery), Short-Term assessments (~1 month post-surgery) and Follow-Up assessments (~4 & 11 months post-surgery)
The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IA & IV Part I, II & IV.
3-part questionnaire to assess daily life performance. Measurement tool: total score from 0 up to 128. Low score means a better outcome.
Time frame: Baseline (before surgery), Short-Term assessments (~1 month post-surgery) and Follow-Up assessments (~4 & 11 months post-surgery)
Parkinson's Disease Questionnaire-39 (PDQ-39)
39-item questionnaire to assess daily life performance. Measurement tool: total score from 0 up to 100. Low score means a better outcome.
Time frame: Monthly, from the start of the study until the end of the home-use phase (~12 months)
Activities specific Balance Confidence Questionnaire (ABC-Q)
16-item questionnaire to assess daily life performance. Measurement tool: total score from 0 up to 100. High score means a better outcome.
Time frame: Monthly, from the start of the study until the end of the home-use phase (~12 months)
The Freezing of Gait Questionnaire (FOG-Q)
6-item questionnaire to assess daily life performance. Measurement tool: total score 0 up to 24. High score means a better outcome.
Time frame: Monthly, from the start of the study until the end of the home-use phase (~12 months)
Home-use kinematic monitoring
To assess gait pattern in ecological environment. Measurement tool: changes in position and orientation of the feet through sensors placed on shoes (mm)
Time frame: Weekly, from the start of the study until the end of the home-use phase (~12 months)
Daily falls tracking
To assess daily falls. Measurement tool: number of falls
Time frame: Weekly, from the start of the study until the end of the home-use phase (~12 months)
Satisfaction questionnaire
16-item questionnaire to collect feedback from the therapy. Measurement tool: total score from 0 up to 100.
Time frame: Monthly, from the Short-Term assessments (~1 month post-surgery) until the end of the home-use phase (~12 months)
User Evaluation of Satisfaction with technology (QUEST 2.0)
12-item questionnaire to assess usability of the therapy. Measurement tool: total score from 12 up to 60. Low score means a better outcome.
Time frame: Follow-Up assessments (~4 & 11 months post-surgery)
System Usability Scale (SUS)
Questionnaire to assess usability of the therapy. Measurement tool: total score from 0 to 100. High score means a better outcome.
Time frame: Follow-Up assessments (~4 & 11 months post-surgery)
Montreal Cognitive assessment (MoCA)
30-item test to assess global cognitive function across multiple domains including memory, attention, language, and executive function. Measurement tool: total score from 0 up to 30. High score means a better outcome.
Time frame: Baseline (before surgery), Follow-Up assessments (~4 & 11 months post-surgery) and safety follow-up visits.
Patient Global Impression of Change (PGI-C)
7-point single-item scale assessing the patient's self-reported overall change since the start of treatment. Measurement tool: score from 1 to 7. Low score means a better outcome.
Time frame: Short-Term assessments (~1 month post-surgery), Follow-Up assessments (~4 & 11 months post-surgery), and safety follow-up visits.
Semi-structured interview
Investigator-conducted interview assessing the participant's subjective well-being and the general effect of the therapy on daily life. Measurement tool: qualitative data.
Time frame: Short-Term assessments (~1 month post-surgery), Follow-Up assessments (~4 & 11 months post-surgery), and safety follow-up visits.
Nerve conduction studies (NCS)
To assess status of peripheral nervous system. Measurement tool: electrical activity in the nerve (mV)
Time frame: Baseline assessments
Somato-sensory evoked potential (SSEP)
To assess the transmission of electrical activity from a touch stimulation. Measurement tool: electrical activity in the nerve (mV)
Time frame: Short-term assessments (~1 month post-surgery)
Cortical signal recording
To assess changes in brain activity patterns. Measurement tool: electrical activity in the brain (mV)
Time frame: After surgery, until 18 weeks post-surgery
Kinematic analysis in different therapeutic conditions
Gait circuit to assess gait kinematic changes. Measurement tool: changes in position and orientation of the body through sensors (mm)
Time frame: After surgery, until 18 weeks post-surgery
Muscle analysis in different therapeutic conditions
Gait circuit to assess muscle activity change. Measurement tool: muscle activity through sensors (mV)
Time frame: After surgery, until 18 weeks post-surgery
Plan to share: No
Started Feb 2024 (actual). Primary completion is estimated for Apr 2029, 61 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 61 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ecole Polytechnique Fédérale de Lausanne